Amgen Earnings Approach

S&P 500 (NYSE:SPY) component Amgen (NASDAQ:AMGN) will unveil its latest earnings on Tuesday, October 23, 2012. Amgen is a biotechnology medicines company that discovers, develops, manufactures, and markets medicines for grave illnesses.

Amgen Earnings Preview Cheat Sheet

Wall St. Earnings Expectations: The average analyst estimate is for profit of $1.43 per share, a rise of 3.6% from the company’s actual earnings for the year-ago quarter. During the past three months, the average estimate has moved down from $1.52. Between one and three months ago, the average estimate moved down. It has been unchanged at $1.43 during the last month. For the year, analysts are projecting net income of $6.22 per share, a rise of 18.7% from last year.

Past Earnings Performance: The company is looking to beat analyst estimates for the third quarter in a row. Last quarter, it beat estimates with profit of $1.82 per share against the mean estimate of $1.51. In the prior quarter, the company reported net income of $1.59.

Earnings season is back and more important than ever. Get our newest CHEAT SHEET stock picks now

Stock Price Performance: Between July 24, 2012 and October 17, 2012, the stock price rose $12.83 (16.8%), from $76.38 to $89.20. The stock price saw one of its best stretches over the last year between December 12, 2011 and December 27, 2011, when shares rose for 11 straight days, increasing 12.7% (+$7.26) over that span. It saw one of its worst periods between November 10, 2011 and November 21, 2011 when shares fell for eight straight days, dropping 5.2% (-$2.99) over that span.

A Look Back: In the second quarter, profit rose 8.2% to $1.27 billion ($1.61 a share) from $1.17 billion ($1.25 a share) the year earlier, exceeding analyst expectations. Revenue rose 13.1% to $4.48 billion from $3.96 billion.

Wall St. Revenue Expectations: Analysts predict a rise of 7.9% in revenue from the year-earlier quarter to $4.25 billion.

Key Stats:

On the top line, the company is looking to build on four-straight revenue increases heading into this earnings announcement. Revenue rose 3.4% in the third quarter of the last fiscal year, 3.4% in the fourth quarter of the last fiscal year and 9.2% in the first quarter before increasing again in the second quarter.

Heading into this earnings announcement, net income has dropped 14.6% on average for the last four quarters.

Analyst Ratings: There are mostly holds on the stock with 13 of 25 analysts surveyed giving that rating.

Balance Sheet Analysis: The company’s current ratio of assets to liabilities came in at 3.68 last quarter. Having a ratio above 2:1 is usually considered a good indicator of a company’s liquidity and ability to meet creditor demands.

Stocks with improving earnings metrics are worthy of your extra attention. In fact, “E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our CHEAT SHEET investing framework for this very reason. Don’t waste another minute — click here and get our CHEAT SHEET stock picks now.

(Company fundamentals by Xignite Financials. Earnings estimates provided by Zacks)

Don’t Miss These Additional Hot Stories:

Is Coca-Cola’s Stock a Buy After Earnings?

College Debt Bubble Update: Apollo Comes Back Down to Earth

Are P&G Shares Attractive Now?

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Premium Newsletters

Stock Investor Cheat Sheet

Stock Investor Cheat Sheet®

The ultimate Cheat Sheet for finding winning stock picks.
Learn More

Gold & Silver Newsletter

Gold & Silver

Don't miss one of the biggest bull markets in history! Covers Gold, Silver, Gold & Silver stocks, and miners.
Learn More

Commodities Premium Newsletter

Commodities Premium

There's always a bull market in some sector! Find the best opportunities in commodities.
Learn more

ETF Investing

ETF Investing

At last, a trading system that buys the right ETFs at the right time, time after time!
Learn more

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business